Clinical Trials on 局部晚期癌症 in Singapore
总计649个结果
-
Novartis Pharmaceuticals完全的FGFR1、2 和/或 3 改变的晚期实体瘤 | FGFR1 扩增的鳞状肺癌 | 具有 FGFR3 突变或融合的膀胱癌 | FGFR1 扩增的晚期实体瘤 | FGFR2 扩增的晚期实体瘤 | 具有 FGFR3 突变的晚期实体瘤法国, 西班牙, 台湾, 德国, 荷兰, 新加坡, 美国, 澳大利亚, 大韩民国, 泰国, 以色列, 意大利, 火鸡, 奥地利
-
National University Hospital, Singapore撤销
-
National University Hospital, Singapore未知
-
National University Hospital, SingaporeTan Tock Seng Hospital未知
-
National University Hospital, Singapore未知
-
National Cancer Centre, SingaporeSingapore General Hospital; Terry Fox Foundation; Duke-NUS Academic Medicine Research Institute未知
-
National University Health System, Singapore完全的
-
National University Hospital, Singapore未知Anonymous Donors at Blood Donation Center (NUH)新加坡
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), Singapore完全的
-
Tan Tock Seng HospitalAstraZeneca; Singapore Cancer Syndicate.未知
-
Astellas Pharma Global Development, Inc.完全的
-
Trans Tasman Radiation Oncology GroupBayer; Peter MacCallum Cancer Centre, Australia招聘中
-
National University Hospital, SingaporeSingapore General Hospital未知
-
National Cancer Centre, Singapore未知
-
Taiho Oncology, Inc.主动,不招人晚期或转移性实体瘤 | 晚期或转移性胃癌或胃食管癌 | 髓样或淋巴样肿瘤 (MLN)美国, 西班牙, 火鸡, 香港, 大韩民国, 比利时, 日本, 荷兰, 法国, 德国, 意大利, 瑞典, 英国, 葡萄牙, 新加坡
-
National University Hospital, Singapore未知
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TTY Biopharm终止
-
Tan Tock Seng HospitalRehabilitation Research Institute of Singapore (RRIS); Woodlands Health (WH)尚未招聘
-
AbbVie (prior sponsor, Abbott)Genentech, Inc.完全的
-
University of MalayaNational University Hospital, Singapore; Merck Sharp & Dohme LLC; Cancer Research Malaysia招聘中